中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

129 records (took 0.061 seconds)

    Cyanopyrroles
    14.
    发明申请
    Cyanopyrroles 有权
    青色

    公开(公告)号：US20050256110A1

    公开(公告)日：2005-11-17

    申请号：US11184313

    申请日：2005-07-19

    Applicant: Mark Collins ,  Valerie Mackner ,  Jay Wrobel ,  Lin Zhi ,  Todd Jones ,  James Edwards ,  Christopher Tegley

    Inventor： Mark Collins ,  Valerie Mackner ,  Jay Wrobel ,  Lin Zhi ,  Todd Jones ,  James Edwards ,  Christopher Tegley

    IPC: C07D403/04 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/405 ,  A61K31/536 ,  A61K31/5415 ,  A61P5/34 ,  A61P13/08 ,  A61P15/00 ,  A61P15/14 ,  A61P15/16 ,  A61P15/18 ,  A61P35/00 ,  A61P43/00 ,  C07D413/04

    CPC classification number: C07D403/04 ,  A61K31/405 ,  A61K31/5415 ,  C07D413/04

    Abstract: This invention provides a progesterone receptor antagonist of formula 1 having the structure wherein, T is O, S, or absent; R1, and R2 are each, independently, hydrogen, alkyl, substituted alkyl; or R1 and R2 are taken together form a ring and together contain —CH2(CH2)nCH2—, —CH2CH2CMe2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, or —CH2CH2NR7CH2CH2—; n=1-5; p=1-4; q=1-4; R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA; RA is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R5 is hydrogen, alkyl, or substituted alkyl; R6 is hydrogen, alkyl, substituted alkyl, or CORB; RB is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R7 is hydrogen or alkyl; or a pharmaceutically acceptable salt thereof.

    Abstract translation: 本发明提供具有以下结构的式1的孕酮受体拮抗剂，其中T为O，S或不存在; R 1，R 2和R 2各自独立地为氢，烷基，取代的烷基; 或R 1和R 2一起形成环，并且一起含有-CH 2（CH 2）2 CH 2 CH 2 - ， - CH 2 CH 2 CH 2 CH 2 N 2 CH 2 2 CH 2 - ， - O（CH 2）2 CH 2 - ， - （CH 2 CH 2） O（CH 2 CH 2）q O - ， - CH 2 CH 2 OCH 2 - / SUB CH 2，或CH 2 CH 2，NR 7，CH 2，CH 2， CH 2 - ; n = 1-5; p = 1-4; q = 1-4; R 3是氢，OH，NH 2，烷基，取代的烷基，烯基，取代的烯基，炔基，取代的炔基或COR A。 R A是氢，烷基，取代的烷基，烷氧基，取代的烷氧基，氨基烷基或取代的氨基烷基; R 4是氢，卤素，CN，NH 2，烷基，取代的烷基，烷氧基，取代的烷氧基，氨基烷基或取代的氨基烷基; R 5是氢，烷基或取代的烷基; R 6是氢，烷基，取代的烷基或COR B; R B是氢，烷基，取代的烷基，烷氧基，取代的烷氧基，氨基烷基或取代的氨基烷基; R 7是氢或烷基; 或其药学上可接受的盐。

    Combination regimens using progesterone receptor modulators
    15.
    发明授权
    Combination regimens using progesterone receptor modulators 失效
    使用孕酮受体调节剂的联合治疗方案

    公开(公告)号：US06759408B2

    公开(公告)日：2004-07-06

    申请号：US10141792

    申请日：2002-05-09

    Applicant: Gary S. Grubb ,  Puwen Zhang ,  Eugene A. Terefenko ,  Andrew Fensome ,  Jay E. Wrobel ,  Horace Fletcher, III ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    Inventor： Gary S. Grubb ,  Puwen Zhang ,  Eugene A. Terefenko ,  Andrew Fensome ,  Jay E. Wrobel ,  Horace Fletcher, III ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    IPC: A61K31535

    CPC classification number: A61K31/535 ,  A61K31/56 ,  Y10S514/843 ,  A61K2300/00

    Abstract: This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single substituents or fused; R3 is H, OH, NH2, C1 to C6 alkyl, CORC, or optionally substituted C1 to C6 alkyl, C3 to C6 alkenyl, or alkynyl; RC is H, or optionally substituted C1 to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, or optionally substituted C1 to C6 alkyl, alkynyl, C1 to C6 alkoxy, amino, or C1 to C6 aminoalkyl; and R5 is a benzene ring, a five or six membered heterocyclic ring; or pharmaceutically acceptable salt thereof. Methods of treatment include contraception, secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, carcinomas, adenocarcinomas minimization of side effects, or food intake stimulation.

    Abstract translation: 本发明涉及使用具有通式结构的孕酮受体的拮抗剂的取代的二氢吲哚衍生物化合物的环状组合疗法和方案：其中R 1和R 2可以是单个取代基或稠合的; R 3是H，OH，NH 2，C 1 -C 6烷基，COR C或任选取代的C 1 -C 6烷基，C 3至C 6烯基或炔基; R C是H或任选取代的C 1至C 3烷基，芳基，C 1至C 3烷氧基或C 1至C 3氨基烷基; R 4是H，卤素，CN，NO 2或任选取代的C 1至C 6烷基，炔基，C 1至C 6烷氧基，氨基或C 1至C 6氨基烷基; 和R 5为苯环，五或六元杂环; 或其药学上可接受的盐。 治疗方法包括避孕，继发性闭经，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征，癌，腺癌最小化副作用或食物摄取刺激。

    Cyclic urea and cyclic amide derivatives
    19.
    发明授权
    Cyclic urea and cyclic amide derivatives 失效
    环状脲和环状酰胺衍生物

    公开(公告)号：US06369056B1

    公开(公告)日：2002-04-09

    申请号：US09552356

    申请日：2000-04-19

    Applicant: Puwen Zhang ,  Arthur A. Santilli ,  Andrew Fensome ,  Eugene A. Terefenko ,  Andrew Q. Viet ,  Jay E. Wrobel ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    Inventor： Puwen Zhang ,  Arthur A. Santilli ,  Andrew Fensome ,  Eugene A. Terefenko ,  Andrew Q. Viet ,  Jay E. Wrobel ,  James P. Edwards ,  Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi

    IPC: A61K31535

    CPC classification number: C07D498/04

    Abstract: This invention provides compounds of the formula: wherein: A, B and D are N or CH, with the proviso that A, B and D can not all be CH; R1 and R2 are independent substituents selected from H, CORA, NRBCORA, or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or groups; or R1 and R2 are fused to form an optionally substituted 3 to 8 membered spirocyclic or heterocyclic ring; RA is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; RB is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl; R3 is H, OH, NH2, or optionally substituted alkyl, or alkenyl, or CORC; RC is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R4 is a substituted benzene ring or a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR5; RF is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; RG is H, alkyl, or substituted alkyl; R5 is H or alkyl; Q is O, S, NR6, or CR7R8; R6 is CN, SO2CF3, or optionally substituted alkyl, cycloalkyl, aryl, or heterocyclic ring; R7 and R8 are H, NO2, CN CO2R9, or optionally substituted alkyl, cycloalkyl, aryl, or heterocyclic; R9 is C1 to C3 alkyl; or CR7R8 form a six membered ring of the structure below: W is O or a chemical bond; or a pharmaceutically acceptable salt thereof, as well as their use and pharmaceutical compositions as agonists and antagonists of the progesterone receptor.

    Abstract translation: 本发明提供下式的化合物：其中：A，B和D为N或CH，条件是A，B和D不能全部为CH; R1和R2是选自H，CORA，NRBCORA或任选取代的烷基，烯基，炔基，环烷基，芳基或基团的独立取代基; 或R 1和R 2稠合形成任选取代的3至8元螺环或杂环; RA为H或任选取代的烷基，芳基，烷氧基或氨基烷基; RB是H，C 1至C 3烷基或取代的C 1至C 3烷基; R3是H，OH，NH2或任选取代的烷基或烯基或CORC; RC为H或任选取代的烷基，芳基，烷氧基或氨基烷基; R4是取代的苯环或具有1,2或3个杂原子的五或六元环，所述杂原子包括O，S，SO，SO 2或NR 5; RF是H或任选取代的烷基，芳基，烷氧基或氨基烷基; RG是H，烷基或取代的烷基; R5是H或烷基; Q是O，S，NR6或CR7R8; R6是CN，SO2CF3或任选取代的烷基，环烷基，芳基或杂环; R 7和R 8是H，NO 2，CN CO 2 R 9或任选取代的烷基，环烷基，芳基或杂环; R9为C1至C3烷基; 或CR7R8形成以下结构的六元环：W为O或化学键; 或其药学上可接受的盐，以及它们的用途和药物组合物作为孕激素受体的激动剂和拮抗剂。

Patent Agency Ranking